You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Measuring toxicant effects on cellular function in a microarray format
SBC: CIENCIA INC Topic: 113Project Summary/Abstract – The EPA maintains a Toxics Release Inventory of andgt;650 toxic chemicals that are disposed or released from andgt;20,000 industrial sites in the United States, while HHS and USDA maintain a list of over 60 select agents and toxicants that pose a severe risk to human, animal, and plant health. These compounds represent only a fraction of the known and unknown environme ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
BlueBox: A Complete Code Blue Data Recorder, Phase II
SBC: NeoVative, Inc. Topic: 400“Code blue” is the signal used in hospitals to call for an immediate cardiopulmonary resuscitation (CPR) following a cardiac or respiratory arrest. Reviewing the performance of the “code blue team” is a cornerstone for improving outcomes. The current standard of using handwritten records on a paper “code sheet” does not allow measurement of key quality indicators and is subject to huma ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes
SBC: Op-T-Mune, Inc Topic: NIAIDType 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of OCF001 for Treatment of Yeast Infections
SBC: Sano Chemicals, Inc. Topic: NIAIDProject Summary Occidiofungins (A-D) are cyclic nonribosomally synthesized antifungal peptides with submicromolar fungicidal activity against a broad spectrum of fungi. Optimization of the production and isolation of occidiofungins from liquid cultures has been performed. The production and isolation of predominantly one analog, called occidiofungin B (OCF001), supports its commercial development ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders
SBC: CETYA THERAPEUTICS, INC. Topic: NHLBIPROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette users
SBC: AUTOMATE SCIENTIFIC, INC. Topic: NIDAAbstract E cigarettes (E-cigs) are increasingly popular worldwide, in particular, among youths. E-cigs may contribute to nicotine addiction and are unlikely to discourage conventional cigarette smoking. Mainstream and second-hand E-cig aerosols contain, in addition to nicotine, detectable levels of toxins including carcinogens and heavy metals such as formaldehyde, benzene, nitrosamines, cadmium a ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Next Generation Tools for Onsite Monitoring and Treatment of Drug of Abuse-Dependent Persons
SBC: SensoDX II, LLC Topic: NIDAAbstract Opioid abuse disorder (OAD) affects 2.1 million of Americans annually resulting in overdoses numbering in the tens of thousands and skyrocketing rates of mortality. In addition to its enormous social impact, OAD carries a multi-billion-dollar price tag that includes $78.5 billion, specifically for health care and other costs related to prescription opioid abuse and misuse. Although effect ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting glioblastoma stem-like cells with custom-designed viral vectors
SBC: Lacerta Therapeutics, Inc. Topic: 102Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
SBC: Longeveron LLC Topic: NIAThe metabolic syndrome (MetS) is a cluster of factors that increases the risks for cardiovascular disease, type 2 diabetes mellitus, and mortality, and currently affects andgt; 40% of US adults. MetS is associated with endothelial dysfunction, decreased circulating endothelial progenitor cells (EPCs), and a pro-inflammatory state. We have made the exciting discovery that therapy with allogeneic me ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Optical photothermal IR (O-PTIR) microscopy for chemical imaging of living cells at sub-micron resolution
SBC: PHOTOTHERMAL SPECTROSCOPY CORP. Topic: 102Optical photothermal IR (OPTIR) microscopy for chemical imaging of living cells at sub-micron resolution Project Summary/Abstract Photothermal Spectroscopy Corp (PSC) and Prof. Ji-Xin Cheng of Boston University in collaboration with Prof. Rohith Reddy (University of Houston) propose to develop, validate, and commercialize a novel technical called Optical Photothermal Infrared (OPTIR) spectroscopy. ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health